U.S. Cardiologist Reports Successful Treatment of Cardiovascular Disease Using Patients' Own Adult Stem Cells 

Clinical Results of Adult Stem Cell Therapy Presented at International Regenerative Biomedical Technology Conference

Pre-treatment MUGA June 17, 2008: Nuclear heart function tests before and after Adult Stem Cell Therapy show a 50 percent improvement in heart function in just four months. (Graphic: Business Wire)

DUBAI, U.A.E.--()--In a report unprecedented in the healthcare industry, Zannos Grekos, MD presented clinical data this week to the Dubai Congress on Regenerative Biomedical Technologies demonstrating the successful treatment of end-stage cardiac diseases using Autologous Adult Stem Cell Therapy. Dr. Grekos offered cardiac nuclear scans, PET scans, and echocardiographs performed at six months and one year post-treatment, which confirm the regeneration of damaged heart tissue, the existence of new blood vessels and a dramatic improvement in heart function in patients treated with adult stem cells extracted from their own blood.

This is real science, real medicine and real results, Grekos stated. We have moved beyond bench research and clinical trials to show that the power of the bodys adult stem cells can be harnessed. Our success rate in reversing ischemic cardiomyopathy and congestive heart failure is extremely high and with our latest technology were capturing the same astounding cell regeneration results in other disease classifications.

Grekos, who is chief medical officer for Florida-based stem cell center Regenocyte Therapeutic, also announced that his team of physicians and scientists successfully treated a patient with Fabry disease - a previously untreatable enzyme deficiency which leads to heart and kidney failure. The patients ejection fraction (EF) increased from 28 to 41 in just four months out from Adult Stem Cell Therapy (normal EF is 55.)

According to Dr. Grekos, The patient no longer needs a heart transplant, which was previously the only means for arresting this disease. His kidney dialysis time has already been reduced by 10 percent, so we are looking at treating his kidney function in the near future.

Athina Kyritsis, MD and chair of Regenocytes medical advisory committee, states, As a physician I find one of the most exciting things this discovery offers is the potential to address many diseases currently believed to be untreatable. We are leaping off of medicines cutting edge; this is no longer just theory.

The Treatment Process

Adult stem cells are extracted from a patient via a standard blood draw. This small, naturally occurring stem cell population is sent to a biotechnology laboratory where it is grown into millions of cells which are engineered to migrate to the part of the body needing repair. The patient receives the new cells one week later through an advanced injection and/or infusion delivery system. Unlike surgically implanted devices, medications, or organ replacement surgery, using a patient's own stem cells to rebuild damaged tissue means there is no possibility of rejection or tumorgenicity (cancer causing).

About the Physician

Zannos Grekos, MD is an interventional cardiologist based in Florida. He is chief medical officer for Regenocyte Therapeutic, one of the world's first clinically treating adult stem cell centers. He is associate clinical professor of Cardiology for Nova Southeastern University and has been appointed to the Science Advisory Board of Washington, D.C.s Repair Stem Cell Institute. In February 2007, he was invited to brief the United States Senate Health Advisory Staff on the current state of stem cell research and therapy.

Regenocyte Therapeutic is currently using Adult Stem Cell Therapy to treat Congestive Heart Failure, Cardiomyopathy, Peripheral Artery Disease, Coronary Artery Disease, Kidney Disease, Ischemic Heart Disease, Pulmonary Disease and Early Senile Dementia. Clinical trials will begin in 2009 for patients with macular degeneration and various neurological diagnoses. Patients can call 866-216-5710 for information or consultation.

Contacts

Regenocyte Therapeutic
Media contact:
Beth S. Kalvin, Director of Communications & Education
239-495-2252 x306; 239-777-2227 cell
bkalvin@regenocyte.com
or
Investors contact:
Paul Schwartz, Chief Operating Officer
239-495-2252 x311
pschwartz@regenocyte.com

Contacts

Regenocyte Therapeutic
Media contact:
Beth S. Kalvin, Director of Communications & Education
239-495-2252 x306; 239-777-2227 cell
bkalvin@regenocyte.com
or
Investors contact:
Paul Schwartz, Chief Operating Officer
239-495-2252 x311
pschwartz@regenocyte.com